Summary:
Living with diabetes is complicated, but not having to take medicine for six months could make life a little easier and may result in better control of diabetes.
ITCA 650 is an investigational drug product that is being developed by Intarcia Therapeutics, Inc. for the treatment of Type 2 Diabetes. When placed under the skin, the slender ITCA 650 device delivers exenatide via osmosis at a slow and consistent rate for up to six months. This constant release of medication, referred to as "zero order" in clinical studies, may have several advantages for treatment of patients with type 2 diabetes.
Qualified Participants Must:
• Have type 2 diabetes
•
Be taking Metformin
•
Be taking Victoza (Liraglutide)
•
Be between 18 and 80 years of age
Qualified Participants May Receive:
A small investigational device (ITCA 650) to release exenatide, the active ingredient in another approved medication, to help control your blood sugar levels over a period of up to 6 months, without the need for daily liraglutide; Monetary reimbursement for their time and travel.